Publicaciones en las que colabora con Eulogio Conde García (17)

2017

  1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

  2. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2014

  1. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

  2. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: A multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study

    British Journal of Haematology, Vol. 164, Núm. 5, pp. 668-674

  3. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

    Haematologica

2013

  1. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

    Haematologica, Vol. 98, Núm. 10, pp. 1563-1570

2012

  1. High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry

    Biology of Blood and Marrow Transplantation, Vol. 18, Núm. 5, pp. 788-793

2009

  1. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas

    Cancer, Vol. 115, Núm. 16, pp. 3728-3737

  2. Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma

    Leukemia and Lymphoma, Vol. 50, Núm. 4, pp. 571-581

2008

  1. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO study group

    European Journal of Haematology, Vol. 80, Núm. 3, pp. 227-235

2002

  1. Myeloablative treatments for multiple myeloma: Update of a comparative study of different regimens used in patients from the Spanish Registry for transplantation in multiple myeloma

    Leukemia and Lymphoma, Vol. 43, Núm. 1, pp. 67-74

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

  2. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma

    British Journal of Haematology, Vol. 109, Núm. 1, pp. 138-147

1997

  1. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: A retrospective study from the Spanish GEL-TAMO cooperative group

    Bone Marrow Transplantation, Vol. 20, Núm. 4, pp. 283-288

1994

  1. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the spanish cooperative group GEL/TAMO

    Bone Marrow Transplantation, Vol. 14, Núm. 2, pp. 279-286

1993

  1. Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: A report from the Spanish GEL/TAMO Cooperative Group

    Annals of Hematology, Vol. 67, Núm. 3, pp. 111-114

1992

  1. Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy

    Bone Marrow Transplantation, Vol. 10, Núm. 1, pp. 33-38